PELO facilitates PLK1-induced the ubiquitination and degradation of Smad4 and promotes the progression of prostate cancer

Research output: Journal Publications and Reviews (RGC: 21, 22, 62)21_Publication in refereed journalpeer-review

View graph of relations

Author(s)

  • Ping Gao
  • Jing-Lan Hao
  • Qian-Wen Xie
  • Gui-Qin Han
  • Bin-Bing Xu
  • Hang Hu
  • Na-Er Sa
  • Xiao-Wen Du
  • Hai-Long Tang
  • Xiao-Ming Dong

Related Research Unit(s)

Detail(s)

Original languageEnglish
Pages (from-to)2945–2957
Journal / PublicationOncogene
Volume41
Issue number21
Online published18 Apr 2022
Publication statusPublished - 20 May 2022

Abstract

PLK1 and Smad4 are two important factors in prostate cancer initiation and progression. They have been reported to play the opposite role in Pten-deleted mice, one is an oncogene, the other is a tumor suppressor. Moreover, they could reversely regulate the PI3K/AKT/mTOR pathway and the activation of MYC. However, the connections between PLK1 and Smad4 have never been studied. Here, we showed that PLK1 could interact with Smad4 and promote the ubiquitination and degradation of Smad4 in PCa cells. PLK1 and PELO could bind to different domains of Smad4 and formed a protein complex. PELO facilitated the degradation of Smad4 through cooperating with PLK1, thereby resulting in proliferation and metastasis of prostate cancer cell. Changes in protein levels of Smad4 led to the alteration of biological function that caused by PLK1 in prostate cancer cells. Further studies showed that PELO upregulation was positively associated with high grade PCa and knockdown of PELO expression significantly decreased PCa cell proliferation and metastasis in vitro and vivo. PELO knockdown in PCa cells could enhance the tumor suppressive role of PLK1 inhibitor. In addition, blocking the interaction between PELO and Smad4 by using specific peptide could effectively inhibit PCa cell metastasis ability in vitro and vivo. Overall, these findings identified a novel regulatory relationship among PLK1, Smad4 and PELO, and provided a potential therapeutic strategy for advanced PCa therapy by co-targeting PLK1 and PELO.

Citation Format(s)

PELO facilitates PLK1-induced the ubiquitination and degradation of Smad4 and promotes the progression of prostate cancer. / Gao, Ping; Hao, Jing-Lan; Xie, Qian-Wen; Han, Gui-Qin; Xu, Bin-Bing; Hu, Hang; Sa, Na-Er; Du, Xiao-Wen; Tang, Hai-Long; Yan, Jian; Dong, Xiao-Ming.

In: Oncogene, Vol. 41, No. 21, 20.05.2022, p. 2945–2957.

Research output: Journal Publications and Reviews (RGC: 21, 22, 62)21_Publication in refereed journalpeer-review